Eiko Lifesciences Ltd (EIKO) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Eiko Lifesciences Ltd ₹52.17, price ₹48.67, upside +7.2%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹32.15 – ₹86.66 · fair‑value band ₹35.24 – ₹72.63 · the ₹48.67 price screens below the ₹52.17 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Eiko Lifesciences in your weekly email
Every Wednesday you see whether Eiko Lifesciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Eiko LifeSciences Limited manufactures and sells specialty and fine chemicals in India. The company operates through Specialty Chemicals; Pharma Intermidiates; Food Additives; Oleo Chemicals; and Cosmetic Ingredients segments. The company offers organic and inorganic specialty chemicals.
Show more
Eiko LifeSciences Limited manufactures and sells specialty and fine chemicals in India. The company operates through Specialty Chemicals; Pharma Intermidiates; Food Additives; Oleo Chemicals; and Cosmetic Ingredients segments. The company offers organic and inorganic specialty chemicals. Its products are used in pharmaceuticals, agrochemicals, aroma chemicals, electronic chemicals, etc. In addition, the company is involved in processing, formulating, producing, buying, selling, and exporting of specialty and fine chemicals. The company was formerly known as Narendra Investments (Delhi) Limited and changed its name to Eiko LifeSciences Limited in June 2021. Eiko LifeSciences Limited was incorporated in 1977 and is based in Thane, India.
Stock analysis
Eiko Lifesciences Ltd (EIKO) currently trades at ₹48.67, while our model-based Fair Value estimate is ₹52.17, so the stock looks roughly fairly valued today (gap 6.7%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹132.15 per share, and 19 of the 23 models we run sit above the ₹48.67 price.
Bear case: the Asset-Based group reads lowest at ₹31.45, and 4 of the 23 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹35.24 (bear) to ₹72.63 (bull), the price of ₹48.67 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Basic Materials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Eiko Lifesciences Ltd reported revenue of ₹527M in FY2026 versus ₹254M in FY2022, a compound +20.0%/yr. Reported net income was ₹45.0M in FY2026, compounding +58.9%/yr from FY2022.
Key figures
Market cap ₹773M (≈ $8.0M) · P/E ratio 14.7 · P/S ratio 1.25 · EPS (TTM) ₹3.29 · Net margin 8.5% · Return on equity 8.4% · Return on assets (EBIT) 3.1% · Operating margin 10.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 22% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −39% fair-value upside, at 7%, EIKO screens cheaper than that median.
Fair Value models
Bear ₹35.24Fair Value ₹52.17Bull ₹72.63
Price ₹48.67 · Upside +7.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹1.69 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.76/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+39.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.7%
Start year 2021 (pandemic)
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+17.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.4%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 12%
2026 sits 287% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+18.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +13.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 694 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside+7.2% · Above median
Profitability
Return on equity (TTM)8.4% · Above median
Return on assets5.2% · Above median
Net margin (TTM)8.3% · Above median
Operating margin (TTM)10.1% · Above median
Growth and dividend
Revenue growth56.4% · Top 25%
Balance sheet
Debt / equity0.04× · Below median
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Eiko Lifesciences Ltd (EIKO) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹52.17 versus a price of ₹48.67, about +7% upside (fairly valued).
What is the fair value of EIKO?
Our model-based fair value for Eiko Lifesciences Ltd is ₹52.17 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹48.67.
What is the quality score of EIKO?
Eiko Lifesciences Ltd has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Eiko Lifesciences Ltd (EIKO)?
Our model-based price target is the fair value of ₹52.17 (as of Sep 27, 2026) from 23 valuation models. Cautious scenario ₹35.24, optimistic scenario ₹72.63. It is a calculation from audited fundamentals, not an analyst target.
What is the Eiko Lifesciences Ltd stock forecast for 2026?
Our models put fair value at ₹52.17, about +7% upside versus a price of ₹48.67 (fairly valued). Cautious scenario ₹35.24, optimistic scenario ₹72.63. The calculation is refreshed regularly with new filings.
What is the revenue of Eiko Lifesciences Ltd (EIKO)?
Eiko Lifesciences Ltd reported trailing-twelve-month revenue of about ₹587M (latest available figure, as of Sep 27, 2026).
What growth is priced into Eiko Lifesciences Ltd (EIKO)?
For today's price to be fair in a discounted-cash-flow model, Eiko Lifesciences Ltd would have to grow free cash flow by +18.1 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +33.7 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of EIKO use?
Our models discount Eiko Lifesciences Ltd at 10.9 %: a base by market capitalisation (nano), damped by beta 0.26, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Eiko Lifesciences Ltd that is +18.1 % per year a year over ten years, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has Eiko Lifesciences Ltd (EIKO) delivered so far?
Over the past 5 years revenue at Eiko Lifesciences Ltd grew +33.7 % a year. The price currently implies +18.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Eiko Lifesciences Ltd (EIKO) growing?
The median revenue growth in the sector is +8.9 % a year. That is the yardstick for the growth priced into Eiko Lifesciences Ltd (+18.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Eiko Lifesciences Ltd (EIKO)?
The free-cash-flow yield on the price is 3.24 %: that much free cash flow Eiko Lifesciences Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Eiko Lifesciences Ltd (EIKO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Eiko Lifesciences Ltd it is ₹52.17 per share (as of Sep 27, 2026), against a price of ₹48.67. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Eiko Lifesciences Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, EIKO trades below its calculated fair value: price ₹48.67, fair value ₹52.17, a gap of about +7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EIKO?
No. The price is what the market pays today (₹48.67); the fair value is what the company's own numbers justify (₹52.17). For Eiko Lifesciences Ltd the two are ₹3.50 per share apart. That gap is exactly why we show both numbers side by side.
How much is Eiko Lifesciences Ltd worth?
The market values Eiko Lifesciences Ltd at about ₹773M (market capitalisation, as of Sep 27, 2026). Per share that is ₹48.67; our models calculate a fair value of ₹52.17 per share.
What do the bullish and bearish scenarios say about EIKO?
Our models span a range for Eiko Lifesciences Ltd: cautious scenario ₹35.24, base ₹52.17, optimistic ₹72.63 per share (as of Sep 27, 2026, price ₹48.67). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EIKO?
Eiko Lifesciences Ltd trades at a price-to-earnings ratio of 14.7 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹52.17 is built from several models across several years. Other multiples: P/B 1.1, P/S 1.3, EV/EBITDA 8.4.
How solid is the balance sheet of Eiko Lifesciences Ltd (EIKO)?
Balance-sheet figures for Eiko Lifesciences Ltd (as of Sep 27, 2026): return on equity 8.4%, debt of 0.04 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is EIKO from its 52-week high?
Eiko Lifesciences Ltd trades at ₹48.67, about 22% below its 52-week high of ₹62.03 and 11% above the low of ₹43.87 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹52.17 is for.
Which stocks are comparable to Eiko Lifesciences Ltd?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Eiko Lifesciences Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price ₹48.67, calculated fair value ₹52.17 (+7%), Quality Score 48/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EIKO calculated?
We run Eiko Lifesciences Ltd through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹52.17, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Eiko Lifesciences Ltd currently trades 7 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Eiko Lifesciences Ltd (EIKO)?
The closing price on Oct 1, 2026 was ₹48.67. Our model-based fair value is ₹52.17, about +7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Eiko Lifesciences Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (₹35.24 to ₹72.63) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Eiko Lifesciences Ltd
How large is the market capitalisation of Eiko Lifesciences Ltd (EIKO)?
The market capitalisation of Eiko Lifesciences Ltd is ₹773M (≈ $8.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Eiko Lifesciences Ltd (EIKO)?
The price-to-sales ratio of Eiko Lifesciences Ltd is 1.25 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Eiko Lifesciences Ltd (EIKO)?
Earnings per share at Eiko Lifesciences Ltd are ₹3.29 (price ÷ EPS = P/E 14.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Eiko Lifesciences Ltd (EIKO)?
The net margin of Eiko Lifesciences Ltd is 8.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Eiko Lifesciences Ltd (EIKO)?
The return on equity (ROE) of Eiko Lifesciences Ltd is 8.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Eiko Lifesciences Ltd (EIKO)?
On an EBIT basis the return on assets of Eiko Lifesciences Ltd is 3.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Eiko Lifesciences Ltd (EIKO)?
The operating margin of Eiko Lifesciences Ltd is 10.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Eiko Lifesciences Ltd (EIKO)?
Revenue at Eiko Lifesciences Ltd is growing +56.4% versus a year earlier (3y avg +42.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Eiko Lifesciences Ltd (EIKO)?
Earnings per share at Eiko Lifesciences Ltd are growing +15.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Eiko Lifesciences Ltd (EIKO) carry?
The net debt of Eiko Lifesciences Ltd is ₹44.1M (fiscal year 2022, ≈ 1.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Eiko Lifesciences Ltd in the live analysis
One click puts Eiko Lifesciences Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
